Pressure Injuries, Agency Staff, and a Thirty-Day Vendor Offer
You manage a 30-bed medical intensive care unit. Unit-acquired pressure injury rates went from 4.1 to 8.3 per 1,000 patient days over two quarters. During the same period, RN turnover reached 34%, twelve of your thirty core RNs have less than one year of ICU experience, and agency staff cover roughly 40% of shifts. The wound care nurse recommends a new repositioning protocol plus a powered support surface. A vendor, aware of the unit's numbers, offers a free 30-day trial of twenty overlay mattresses if the hospital signs a three-year contract within 30 days. The unit practice council is enthusiastic and wants to start a "quick PDSA cycle next week" with the overlays and the new protocol together. Your CNO asks for a plan.
1. Sequence your response. What happens first, what waits, and why not start with the mattress?
Read the worked answer
First: validate the outcome measure before treating it as a signal. Review each injury - was it present on admission, is the staging consistent, did a change in wound-care surveillance or a new wound nurse increase detection? A doubling over two quarters in a unit with 40% agency coverage is as likely to be a measurement or documentation artifact as a true clinical deterioration.
Second: check the bundle elements you already own. Risk assessment completed and acted on, repositioning documented (and do you have enough functioning lifts to reposition a 300-pound patient with two nurses?), nutrition consults for at-risk patients, moisture management, and the condition of the existing surfaces.
Why not the mattress first:
- A new surface cannot substitute for repositioning. With 40% agency staff and a third of core nurses under one year, the dominant driver is almost certainly not the bed - it is consistency and staffing.
- Bundling the surface and the protocol in one "quick PDSA" makes the results uninterpretable. If injuries fall, you will not know which change worked, and you will have committed three years of budget on an unproven attribution.
- The 30-day contract deadline is a sales construction, not a clinical one. Urgency generated by a vendor is a reason to slow down.
Sequence: validate data → stabilize the workforce and bundle reliability → measure → then evaluate the surface as a discrete decision with evidence.
2. How do you handle the vendor's offer, and what are the organizational and ethical risks?
Read the worked answer
Sever the trial from the contract. Accept a trial only with written terms: no obligation to purchase, defined duration and removal terms, no auto-renewal, and no exclusivity language. If the vendor will not separate them, decline - that refusal is the most useful information you will get.
Risks to name:
- Sole-source commitment without evaluation. Signing in 30 days forecloses comparison with products already on the system's GPO contract and skips capital or value-analysis review.
- Inducement and conflict-of-interest exposure. Free product tied to a purchase can raise compliance and anti-kickback concerns depending on structure; supply chain and your director need to see the offer before anything is signed.
- Anchoring and urgency as a decision tool. A deadline set by the seller is designed to prevent exactly the deliberation you need.
- Reputational and financial. If injuries do not improve, you own three years of cost and a lost opportunity.
What to do: route it through supply chain and the value-analysis process, disclose the offer in writing to your director, and ask the vendor for their clinical evidence and a no-strings evaluation. Staff enthusiasm for a product is real data about their experience - it is not evidence of effectiveness, and the practice council should hear that distinction explicitly so the eventual decision does not feel like a rejection of their judgment.
3. What measures will you track, and how do you avoid attributing improvement to the intervention prematurely?
Read the worked answer
Outcome: unit-acquired pressure injuries per 1,000 patient days, by stage, with an explicit case definition and independent validation of staging - plus the raw count, since a small unit makes rates volatile.
Process: risk assessment completed within 24 hours, repositioning documented per protocol, appropriate surface in use, nutrition consult for at-risk patients, and - diagnostically important here - agency and new-grad orientation completion on the bundle.
Balancing: falls (a repositioning push can increase handling), staff time per turn, and cost per patient day.
Avoiding premature attribution:
- Display data on a run chart or SPC chart with the intervention date annotated, and do not interpret a shift until you have enough points to distinguish signal from common-cause variation.
- Re-examine the baseline for surveillance artifact; if the definition changed, rebase rather than celebrate.
- Beware regression to the mean: two bad quarters are followed by better ones for reasons unrelated to you.
- Pre-specify the evaluation window and the criteria for abandoning the change before you start. Announcing success at month one is how units keep ineffective practices for years.
- Adjust or at least describe acuity and experience mix, because your staffing changed at the same time as everything else.